Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 370 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Camrelizumab Plus Rivoceranib Versus Sorafenib As First-Line Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Cost-Utility Analysis in China and the United States
Qiuling Zhao, Yimin He, Zilin Nian, Yongjian Huang, Ruyi Huang, Lijun Lai,Lin Yang
Frontiers in pharmacology (2025): 1404389-1404389
Cited0Views0WOSBibtex
0
0
CD8+CD28+PD1− T Cells As a Prognostic Biomarker in Endometrial Cancer
Yufei Nie,Lin Yang, Yanan Zhang,Hongyan Guo
Current oncology (Toronto, Ont)no. 3 (2025)
Cited0Views0WOSBibtex
0
0
ATAD2 is a Potential Immunotherapy Target for Patients with Small Cell Lung Cancer Harboring HLA-A∗0201
Li Yuan, Sini Li, Yixiang Zhu,Lin Yang,Xue Zhang,Yan Qu,Zhijie Wang,Jianchun Duan,Jia Zhong,Yanhua Tian,Lihui Liu, Boyang Sun,Kailun Fei, Zheng Liu,Jian Zhang, Yan He, Yufeng Guo, DanMing He, Wei Zhuang, Jinsong Zhang
eBioMedicine (2025): 105515
Cited0Views0WOSBibtex
0
0
Load More
Author Statistics

#Papers: 370

#Citation: 5695

H-Index: 38

G-Index: 62

Sociability: 7

Diversity: 4

Activity: 125

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn